Haohai Biological Technology Balanced Scorecard

It highlights how well Haohai turns R&D into marketable healthcare products. Because the company spans 4 therapeutic areas and 3 core functions-R&D, manufacturing, and sales-the scorecard is most useful when it tracks innovation output, batch quality, and revenue growth together. That combination is more informative than profit alone.

It can link new-product development to plant execution and customer adoption. For Haohai, the best growth dashboard usually includes 3 metrics: R&D pipeline progress, on-time manufacturing release, and repeat sales by product line. That matters in a business selling devices, biomaterials, and pharmaceuticals because growth can stall if any one stage slips.

Visibility into quality and execution matters most. Investors should want to see 4 scorecard areas aligned around margin, complaint rates, approval timelines, and cash conversion, especially because Haohai sells regulated medical products and hyaluronic acid injections. If those indicators improve together, earnings quality is usually stronger than a simple sales spike.

The main drawbacks are data burden and over-weighting internal metrics. Haohai operates across 4 therapeutic areas, so the scorecard can become noisy if each unit reports different definitions for R&D spend, defect rates, and launch timing. Without strict standardization, managers may optimize scores instead of improving real business performance.

Regulatory and clinical timing limit it most. A Balanced Scorecard can track 3 internal metrics well-R&D spend, manufacturing yield, and sales growth-but it may lag when approval cycles, physician adoption, or reimbursement conditions change quickly. For Haohai, those external factors can move results faster than the scorecard updates.